About VIGIL NEUROSCIENCE, INC.
Vigil Neuroscience, Inc. is a biotechnology company. The Company is a microglia-focused therapeutics company. It is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It utilizes the tools of modern neuroscience drug development across multiple therapeutic modalities to deliver precision-based therapies to improve the lives of patients and their families. The Company's VGL101, a fully human monoclonal antibody targeting human TREM2 for the treatment of rare microgliopathies. It is developing VGL101 for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare, genetically defined, and fatal neurodegenerative disease caused by microglial dysfunction. The Company is also developing a novel small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction.